Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation

Bone

Volumn 32, Issue 1, 2003, Pages 96-106

  Fahrleitner, A ^a,b   Prenner, G ^b   Leb, G ^a,b   Tscheliessnigg, K H ^b   Piswanger Solkner C ^a,b   Obermayer Pietsch, B ^a,b   Portugaller, H R ^b   Berghold, A ^b   Dobnig, H ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cylosporine A; Glucocorticoids; Immunosuppression; Osteoporosis; Transplantation; Vertebral fractures

Indexed keywords

AZATHIOPRINE; CALCIUM; CYCLOSPORIN A; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOPROTEGERIN; PREDNISOLONE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FEMUR NECK; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; HIP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PREVALENCE; PROTEIN BLOOD LEVEL; RECIPIENT; VERTEBRA FRACTURE;

AGED; BONE DENSITY; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPROTEINS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SPINAL FRACTURES; STATISTICS, NONPARAMETRIC;

EID: 0344059210     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00926-2     Document Type: Article

References (50)

1. United Network of Organ Sharing (UNOS) OPTN/SR 1996 annual report - graft/patient survival.
2. Shane E., Rodino M.A., McMahon D.J., Addesso V., Staron R.B., Seibel M.J., Mancini D., Michler R.E., Lo S.H. Prevention of bone loss after heart transplantation with antiresorptive therapy a pilot study. J Heart Lung Transplant. 17:1998;1089-1096.
3. Shane E., Rivas M., McMahon D.J., Staron R.B., Silverberg S.J., Seibel M.J., Mancini D., Michler R.E., Aaronson K., Addesso V., Lo S.H. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 82:1997;1497-1506.
4. Shane E., Rivas M., Staron R.B., Silverberg S.J., Seibel M.J., Kuiper J., Mancini D., Addesso V., Michler R.E., Factor-Litvak P. Fracture after cardiac transplantation a prospective longitudinal study. J Clin Endocrinol Metab. 81:1996;1740-1746.
5. Thiebaud D., Krieg M.A., Gillard-Berguer D., Jacquet A.F., Goy J.J., Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest. 26:1996;549-555.
6. Henderson N.K., Sambrook P.N., Kelly P.J., Macdonald P., Keogh A.M., Spratt P., Eisman J.A. Bone mineral loss and recovery after cardiac transplantation. Lancet. 1995;346-905.
7. Van Cleemput J., Daenen W., Nijs J., Geusens P., Dequeker J., Vanhaecke J. Timing and quantification of bone loss in cardiac transplant recipients. Transplant Int. 8:1995;196-200.
8. Sambrook P.N., Kelly P.J., Keogh A.M., Macdonald P., Spratt P., Freund J., Eisman J.A. Bone loss after heart transplantation a prospective study. J Heart Lung Transplant. 13:1994;116-121.
9. Gillard Berguer D., Krieg M.A., Thiebaud D., Burckhardt P., Stumpe F., Hurni M., Sadeghi H., Kappenberger L., Goy J.J. Osteoporosis in heart transplant recipients a longitudinal study. Transplant Proc. 26:1994;2649-2651.
10. Sambrook P.N., Kelly P.J., Fontana D., Nguyen T., Keogh A., Macdonald P., Spratt P., Freund J., Eismann J.A. Mechanism of rapid bone loss following cardiac transplantation. Osteoporosis Int. 4:1994;273-276.
11. Van Cleemput J., Daenen W., Geusens P., Dequecker J., Van de Werf F., Vanhaecke J. Prevention of bone loss in cardiac transplant recipients. Transplantation. 61:1996;1495-1499.
12. Rozenberg S., Oberlin F., Dorent R., Koeger A.C., Frih L., Gandjbackch I., Bourgeois P. Study of bone mineral density after cardiac transplantation. Transplant Proc. 27:1995;1692-1693.
13. Shane E., Rivas M.D.C., Silverberg S.J., Kim T.S., Staron R.B., Bilezikian J.P. Osteoporosis after cardiac transplantation. Am J Med. 94:1993;257-264.
14. Negri A.L., Perrone S., Gallo R., Bogado C.E., Zanchetta J.R. Osteoporosis following heart transplantation. Transplant Proc. 28:1996;3321-3324.
15. Rich G.M., Mudge G.H., Laffel G.L., LeBoeff M.S. Cyclosporine A and prednisone - associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 11:1992;950-958.
16. Glendenning P., Neil Kent G., Adler B.D., Matz L., Watson I., O'Driscoll G.J., Hurley D.M. High prevalence of osteoporosis in cardia transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol. 50:1999;347-355.
17. Lee A.H., Mull R.L., Keenan G.F., Callegari P.E., Dalinka M.K., Eisen H.J., Mancini D.M., DiSesa V.J., Attie M.F. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 96:1994;35-41.
18. Guo C.Y., Johnson A., Locke T.J., Eastell R. Mechanism of bone loss after cardiac transplantation. Bone. 22:1998;267-271.
19. Simmonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.-S., Lüthy R., Nguyen H.-Q., Wooden S., Bennet L., Boone T., Shimamoto G., DeRose M., Elliot R., Colombero A., Tan H.-L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Lee R., Boyle W.J. Amgen EST Program and Osteoprotegerin a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319.
20. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
21. Yasuda H., Shima N., Nakagawa N., Yamaguch K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiating factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.
22. Hofbauer L.C., Khosla S., Lacey D.L., Dunstan C.R., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 15:2000;2-12.
23. Quinn J.M.W., Elliot J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiating factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
24. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dentritic-cell function. Nature. 390:1997;175-179.
25. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 96:1999;3540-3545.
26. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 253:1998;395-400.
27. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S.C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C.R., Lacey D.L., Boyle W.J. RANK is the intrinsic hematopoetic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA. 97:2000;1566-1571.
28. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med. 3:1998;1285-1289.
29. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;1329-1337.
30. Akatsu T., Murakami T., Ono K., Nishikawa M., Tsuda E., Mochizuki S.I., Fujise N., Higashio K., Motoyoshi K., Yamamoto M., Nagata N., Akatsu T., Murakami T., Ono K., Nishikawa M., Tsuda E., Mochizuki S.I., Fujise N., Higashio K., Motoyoshi K., Yamamoto M., Nagata N. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone. 23:1998;495-498.
31. Bekker P.J., Holloway D., Nakanishi A., Arrighi H.M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 16:2001;348-360.
32. Vidal N.O.A., Brändström H., Jonsson K.B., Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells down-regulation by glucocorticoids. J Endocrinol. 159:1998;191-195.
33. Hofbauer L.C., Riggs B.L., Dunstan C.R., O'Brien T., Khosla S. Cyclosporin A and glucocorticoids inhibit osteoprotegerin production in human osteoblastic and coronary artery smooth muscle cells potential mechanism of post-transplant osteoporosis and vascular disease. J Bone Miner Res. 14:(Suppl. 1):1999;S176.
34. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells potential paracrine mechanism of glucocorticoid-induced osteoporosis. Endocrinology. 140:1999;4382-4389.
35. Genant H.K., Wu C.Y., Van Kulik C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 8:1993;1137-1148.
36. Kanis J.A., Melton L.J., Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 9:1994;1137-1141.
37. Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., Delmas P.D. Osteoprotegerin serum levels in men correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 86:2001;3162-3165.
38. Yano K., Tsuda E., Washida A., Kobayashi F., Goto M., Harada A., Ikeda K., Higashio K., Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 14:1999;518-527.
39. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 86:2001;631-637.
40. Bornefalk E., Dahlen I., Johannsson G., Ljunggren O., Ohlsson C. Serum levels of osteoprotegerin effects of glucocorticoid and growth hormone. Bone. 23M:(Suppl. 1):1998;S136.
41. Sato T., Tominaga Y., Iwasaki Y., Kazama J.J., Shigematsu T., Inagaki H., Watanabe I., Katayama A., Haba T., Uchida K., Fukagawa M. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis. 38:(Suppl.):2001;S175-177.
42. Canalis E. Effects of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid contant in cultured rat calvariae. Endocrinology. 112:1983;931-939.
43. Boncimino K., McMahon D.J., Addesso V., Bilezikian J.P., Shane E. Magnesium deficiency and bone loss after cardiac transplantation. J Bone Miner Res. 14:1999;295-303.
44. Movsowitz C., Epstein S., Ismail F., Fallon M., Thomas S. Cyclosporin A in the oophorectomized rat unexpected severe bone resorption. J Bone Miner Res. 4:1989;393-398.
45. Movsowitz C., Epstein S., Fallon M., Ismail F., Thomas S. Cyclosporin A in vivo produces severe osteopenia in the rat. Effect of dose and duration of administration. Endocrinology. 123:1988;2571-2577.
46. Delmas P.D., Schlemmer A., Gineyts E., Riis B., Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 6:1991;639-644.
47. Christgau S., Bitsch-Jensen O., Hanover Bjarnason N., Gamwell Henriksen E., Qvist P., Alexandersen P., Bank Henriksen D. Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 26:2000;505-511.
48. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 30:2002;307-313.
49. Bu R., McKeon R.M., Cao L., Blair H.C. Osteoprotegerin (OPG) binds TNF family proteins including TNFα and protects osteoblasts from TNFα-induced apoptosis a complementary function in addition to effects of OPG on osteoclast differentiation via RANKL. J Bone Miner Res. 16:(Suppl. 1):2001;S169.
50. Holt M.I., Baattrup A., Eriksen E.F. Expression of osteoclast differentiating factor (ODF, RANKL) and osteprotegerin (OPG) in human bone role of the bone remodeling compartment in the coupling between resorption and formation. J Bone Miner Res. 16:(Suppl 1):2001;S364.